Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Clin Cancer Res. 2021 Aug 18;27(21):5961–5978. doi: 10.1158/1078-0432.CCR-21-0986

Figure 2. Effect of MTL-CEBPA treatment of patients with HCC on gene and protein expression in myeloid cells.

Figure 2.

A. Gene expression profile was evaluated by nanoString® using the human PanCaner IO 360 panel. Heat map of gene expression up regulated (+1> log2 fold change and above) or downregulated (−1< log2 fold change and below) with a false discovery rate (FDR) of <5% is shown. B. Protein expression profile was evaluated by mass spectroscopy. Proteins with p value < 0.05 and absolute log2 fold change > 1 were considered as significantly differentially expressed. Adjusted p values were calculated by correcting for a false discovery rate (FDR) of <5%.